Golub Dobrzyn, Poland
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Total study duration per participant will be up to 58 weeks, including a screening period of up to 4 weeks, a treatment period up to 52 weeks and a post-treatment follow-up period of 2 weeks.
Phase
2Span
212 weeksSponsor
SanofiWloclawek
Recruiting
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
Phase
2Span
183 weeksSponsor
Boehringer IngelheimWloclawek
Recruiting
1-2 of 2